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Summary 
CD4 + T  cells have been shown to be crucial in the development of experimental autoimmune 
myasthenia gravis (EAMG).  The role of CD8 + T  cells  in EAMG is less well established.  We 
previously  showed  that  antibody  depletion  of CD8 +  T  cells  in  rats  effectively  suppresses 
EAMG. To further study the rote and relationship of CD4 + versus CD8 + T  cells in induction 
ofEAMG,  CD4 -/-,  CD8 -/-,  and CD4-8-  mutant C57BL/6 mice and the parent CD4+8 + 
wild-type mice were immunized with Torpedo acetylcholine receptor (ACht  0  plus complete 
Freund's  adjuvant.  Clinical  EAMG  was  nearly  completely prevented  in  CD4-8-,  CD4 -/-, 
and CD8 -/- mice. This was associated with strongly reduced AChR-specific T  and B celt re- 
sponses, and with reduced levels of  AChR-reactive interferon ~/(IFN-'y) and interleukin 4 (IL-4) 
mtLNA-expressing cells  in lymphoid organs when  compared with  CD4+8 + wild-type mice. 
We conclude that  (a) both CD4 + and CD8 + T  cells are essential for development of EAMG, 
and a collaboration between  these cell types may be necessary; (b)  CD4 + as well as CD8 + T 
cells  secrete IFN-y and IL-4, and both cytokines are involved in the development of EAMG; 
and  (c), besides  T  cells,  other immune  cells might also be responsible  for help  of anti-AChtL 
antibody production. 
E 
xperimental  autoimmune myasthenia gravis  (EAMG) 1 
can be induced in susceptible mouse strains by repeated 
injections  of acetylcholine receptor  (AChR)  emulsified  in 
CFA, and serves as a useful animal model for exploring the 
pathogenesis  of human  myasthenia  gravis  (MG)  (1).  The 
muscle weakness and fatigue that are the hallmarks  of my- 
asthenia  gravis  and EAMG  are  due  to an antibody-medi- 
ated  autoimmune  attack  directed  against  AChtL  of the 
neuromuscular  junctions  (2).  The  production  of  anti- 
AChR  antibodies  depends  on  cytokines  produced  by  T 
cells  (3).  T  cell responses  to AChR,  its  subunits,  and  the 
o~-subunit  peptides  have  been  described  in  myasthenia 
gravis (4, 5) and EAMG (6-8). AChtL subunit and peptide- 
specific rat CD4 + T  cells secrete both Thl  (IL-2,  IFN-~/) 
and  Th2  (IL-4)  cytokines  after  stimulation  with  AChR, 
and provide help for anti-AChR antibody production  (3). 
EAMG is suppressed in mice treated with mAb to murine 
1Abbreviations used in this paper: 0~-BGT, ~x-bungarotoxin; AChK, acetyl- 
choline receptor; EAMG, experimental autoimmune myasthenia gravis; 
M-AChlK, muscle AChR extract; MBP, myelin basic protein; MNC, 
mononuclear  cell; p.i., postprimary immunization; MG,  myasthenia 
gravis; PILN, popliteal and inguinal lymph node; SI, stimulation index. 
CD4 +  T  cells  and in mice lacking CD4 +  T  cells,  further 
supporting  a  role  for these  T  cells  in  the  pathogenesis  of 
EAMG (9,  10), 
We have shown that depletion ofCD8 + T  cells in Lewis 
rats also suppresses EAMG and the levels ofanti-AChR an- 
tibodies  (11),  indicating  that  CD8 +  T  cells  are  also  in- 
volved as helper or effector cells in the pathogenesis of this 
disease.  Another  report,  however,  showed  that  [~2  m-/- 
mice,  which are CD8-  and MHC  class I  deficient,  have a 
higher incidence of EAMG than control mice (12). To fur- 
ther analyze the relative  contribution  of CD4 and CD8 T 
cells in the induction of EAMG, we induced the disease in 
CD4 -/-,  CD8 -/-,  and  CD4-8-  mutant  C57BL/6J  mice 
and the same strain of CD4+8 + wild-type mice. 
Materials and Methods 
Animals and Antigen Preparation.  Female  C57BL/6J  (H-2  b) 
CD8 -/-,  CD4 -/-,  and  CD4-8-  mutant  mice  were  obtained 
from  Dr.  Tak  W.  Mak  using  homologous  recombination  in 
pluripotent  embryonic stem cells, and were bred  at  the animal 
house, Division of Immunology, Karolinska  Institute.  The same 
strain  of female  CD4+8 + mice was obtained from the same ani- 
mal house. All mice used were 8-12 wk of age, weighing 20-30 g. 
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Californica (Pacific Biomarine, Venice,  CA)  by affinity chroma- 
tography on an ot-cobrotoxin-agarose resin (Sigma Chemical Co., 
St.  Louis, MO) as described previously (13). The isolated product 
was pure as judged by SDS-PAGE. Muscle AChR extract from 
normal C57BL mice (M-AChR) was prepared as described (13). 
Myelin basic protein (MBP)  used as control antigen was purifed 
from normal mouse brains as described (14). 
Induction of EAMG.  Mice were immunized with 20 p~g Tor- 
pedo AChR emulsified in CFA in a total volume of 100 p  J,  in- 
jected into five intradermal sites  along the back, the  hind foot- 
pads, and the base of the tail (1), and were boosted on days 30 and 
60 after the primary sensitization. The mice were observed every 
other day in a blinded fashion for signs of clinical muscle weak- 
ness. The disease symptoms were graded as follows (9): 0, no def- 
inite muscle weakness; 1 +, normal strength at rest but weak with 
chin on the floor and inability to raise the head after exercise con- 
sisting of 20 consecutive paw grips; 2+, as grade 1+  weakness at 
rest;  and  3+,  moribund,  dehydrated,  and  paralyzed.  Clinical 
EAMG was confirmed by i.p. administration of neostigmine bro- 
mide and atropine sulphate. Mice were killed 100 d postprimary 
immunization (p.i.). 
RIAforM-AChR  Content.  The  concentration of AChR  of 
mouse muscle carcass was determined by ILIA (10). Briefly, tripli- 
cate 2-pmol aliquots of lasI--ot-bungarotoxin (or  Amersham 
Corp.,  Arlington Heights,  IL)-labeled Triton X-100 solubilized 
mouse muscle extract were mixed with a standard pooled mouse 
anti-AChR antiserum. After overnight incubation, rabbit anti- 
mouse  lg  (Dakopatts,  Copenhagen,  Denmark)  was  added.  The 
resulting precipitates were  pelleted,  washed,  and pelleted again. 
Radioactivity of the pellet was counted in a galmna counter (Pack- 
ard  Instrument Co.,  Inc., Meriden,  CT).  AChR  content is  ex- 
pressed as moles of 12sI--o~-BGT binding sites per milligram pro- 
tein of carcass, and the percentage loss of M-AChR in test mouse 
carcass was calculated (13). 
RIA for Serum Anti-AChR Antibodies.  Blood specimens were 
collected from the tail vein just before and then at weekly inter- 
vals, and serum antibody concentrations to M-AChR were mea- 
sured by RIA (13).  Briefly, 1 nmol mouse AChR was incubated 
with 2 nmo112sI--~-BGT. To 1 ml of labeled M-AChR, 1 b~l se- 
rum was added,  followed by rabbit anti-mouse Ig.  The samples 
were centrifuged, washed, and counted in a gamma counter. The 
AChR precipitated minus the background value pemfits calcula- 
tion of the titer in moles of toxin-binding sites bound per liter of 
serum.  Serum samples from  CFA-injected CD4+8 +  mice were 
analyzed in parallel. 
Mononuclear Cell Suspensions.  Suspensions of mononuclear cells 
(MNC)  from  the  popliteal  and  inguinal lymph nodes  (PILN), 
spleen, and thymus were prepared as described (11), and cells were 
suspended in DME supplemented with 1% (vol/vol) MEM (both 
from Gibco, Paisley, UK), 2 mM glutamine (Flow Laboratories, 
lrvine, UK),  50  IU/ml penicillin, 50  I~g/ml streptomycin, and 
10%  (vol/vol) FCS  (Gibco). The  cells  were  washed three times 
and then rediluted to a cell concentration of 2  ￿  10a/ml. 
Enumeration of  A ChR-specific IgG Antibody-secreting Cells.  A  solid- 
phase  enzyme-linked immunospot  assay  (ELISPOT)  was  used 
with  some  modifications (11).  Briefly,  wells  were  coated  with 
100 txI AChR or MBP (I0 b~g/ml in PBS).  AIiquots of 100-bd 
cell suspensions containing 2  ￿  10  s MNC were added in tripli- 
cate to individual wells. After incubation for 24 h, the wells were 
emptied, followed by addition of rabbit anti-mouse IgG (Sigma 
Chemical Co.),  biotinylated swine anti-rabbit IgG  (Dakopatts), 
and avidin-biotin peroxidase  complex  (ABC;  Dakopatts).  After 
peroxidase  staining,  the  red-brown  immunospots  that  corre- 
sponded to cells having secreted anti-AChR IgG were counted and 
standardized to number per l0  s MNC. 
AChR-reactive IFN-y-secreting  Cells.  Nitrocellulose-bottomed 
microtiter plates were coated with 100/.zl rat IFN-~ capture anti- 
body  (DBI;  15)  at  15  ~g/ml.  Aliquots of 200-b~l  suspensions 
containing 4  ￿  105 MNC were added to individual wells in trip- 
licate, followed by antigen (AChR or MBP) or the mitogen Con 
A (Sigma Chemical Co.) in 10-~zl aliquots at a final concentration 
of 10 p~g/ml AChR or MBP,  or 5 ~g/ml Con A. After 48 h  of 
culture, the wells were emptied. Secreted and bound IFN-y was 
visualized by sequential application of polyclonal rabbit anti-rat 
IFN-~  (15),  biotinylated anti-rabbit IgG  (Dakopatts),  and ABC 
(Dakopatts).  After peroxidase staining, the  red-brown immuno- 
spots that corresponded to the cells that had secreted IFN-~/were 
enumerated in a dissection microscope. To calculate the numbers 
of T  cells responding to a particular antigen or mitogen, numbers 
of spots in culture without antigen added were  subtracted from 
the values obtained after antigen or mitogen exposure.  The data 
were expressed as numbers per 10  s MNC. 
Lymphocyte Proliferation Responses.  Triplicate  aliquots  (200  ~zl) 
of MNC  suspensions were  applied to  96-well round-bottomed 
microtiter plates (Nunc, Copenhagen, Denmark) at a cell density 
of 2  ￿  10('/ml. l()-bL1 aliquots of either AChR, MBP, or Con A 
were added to appropriate wells at a final concentration of 1  () b~g/ 
ml (AChR or MBP) or 5 la,  g/ml (Con A). After 60 h of incuba- 
tion, the cells were pulsed for 12 h with 10-lxl aliquots containing 
1  ~Ci  of [~H]methylthymidine (specific  activity,  42  Ci/mmol; 
Amersham Corp.). Cells were harvested onto glass fiber filters and 
thymidine incorporation was measured. The results were expressed 
as stimulation index  (SI),  which  was calculated by dividing the 
counts per minute from culture in the presence of antigen or mi- 
togen by the counts per minute from culture without antigen. 
Detection of IFN-T,  IL-4,  and  TGF-[3  mRNA  Expression by In 
Situ Hybridization.  In situ  hybridization was  performed  as  de- 
scribed (16).  Briefly, 200qxl aliquots of suspensions from  PILN 
containing 4  X  10  s MNC were plated into round-bottomed nil- 
crotiter plates (Nunc, Roskilde, Denmark) in triplicate. 10-1xl  ali- 
quots of either AChR, MBP, or Con A were added to appropri- 
ate wells at a final concentration of 10 Ixg/nd (AChR or MBP) or 
5  Ixg/ml (Con A).  After culture for 24 h,  the cells were washed, 
counted, and dried onto restricted areas  of glass slides  (ProbeOn 
slides;  Fisher  Scientific,  Pittsburgh,  PA).  Synthetic  oligonucle- 
otide probes (Scandinavian Gene Synthesis AB, K6ping, Sweden) 
were labeled using [3sS]deoxyadenosine-5'-c~-(thio)-triphosphate 
with  tenninal deoxynucleotidyl transferase  (Amersham  Corp.). 
To increase the sensivity of the method, a mixture of four differ- 
ent oligonucleotide probes was employed for each cytokine. The 
oligonucleotide  sequences  were  obtained  from  EMBL/Gen- 
Bank/DDBJ using the MacVector software (IBI). The rat IFN-y 
probes (17) (EMBL/GenBank/DDBJ accession numbers M29315, 
M29316,  and M29317)  were  complementary to  bases  298-345 
(exon 1), 80-125 (exon 2), 303-350 (exon 3), and 180-227 (exon 
4).  The rat IL-4 probes  (18)  (EMBL/GenBank/DDBJ  accession 
number X16058)  corresponded to  bases  83-130,  2(i)9-256,  270- 
317,  and 331-378.  The  TGF-IB probes  (19)  (EMBL/GenBank/ 
DDBJ accession number X02812)  were complenlentary to bases 
766-1813 and 1953-2000. The oligonucleotide probes were ap- 
proximately 48 bases tong and checked for the absence of palin- 
dromes or long sequence of homology within the species against 
available  EMBL/GenBank/DDBJ  data.  Cells  were  hybridized 
with 10  (, cpm of labeled probe per 100 hal of hybridization nfix- 
ture. After emulsion autoradiography, development, and fixation, 
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itive ceils containing >15 grains per cell in a starlike distribution. 
The intracellular distribution of the grains was always checked by 
light microscopy, and labeled cells were expressed as numbers per 
lO  s MNC. 
Statistical Analysis.  Overall differences between the four groups 
were evaluated by the Kruskal-Wallis one-way analysis  of vari- 
ance (ANOVA). Student's t test was used for the comparison of 
serum anti-AChR antibodies, and the Mann-Whitney U  test was 
used for the other variables analyzed. All significance tests were 
two-sided. 
Results 
Muscle  Weakness  in  CD4-  and~or  CD8-knockout  Mice. 
One out of 15 wild-type (CD4+8 +)  mice developed mus- 
cle weakness 3 wk after primary sensitization without boost- 
ing.  Seven  more  mice  developed paralysis after boosting. 
These animals deteriorated progressively until two died and 
two were humanely killed (Fig. 1). After the first boosting, 
two CD8 -/-  mice exhibited mild and moderate weakness, 
respectively, lasting to the end. In the CD4 -/- group, one 
mouse got mild EAMG after the first boosting and recov- 
ered about 1 mo later; another mouse developed moderate 
weakness  after  the  second  boosting  and  improved  20  d 
later. Among the  CD4-8-  mutant  mice,  only one  devel- 
oped mild and short-term muscle weakness  12  d  after the 
first boosting (Fig. 1). 
Loss  ofM-AChR.  The  mean  values  for  losses  of 
M-AChR  in the CD4 -/-, CD8 -/-, and CD4-8-  mice af- 
ter immunization with AChR  and  CFA were 21  z  18%, 
29  +-  15%, and 9  +  3%, respectively. In contrast, the mean 
M-AChR  loss in the  CD4+8 +  wild mice was  54  •  11%, 
being  significantly higher  than  in  the  other  three  groups 
(P <0.05,  0.05,  and  0.002,  respectively).  No  differences 
were found among CD4 -/-, CD8 -/-, and CD4-8-  mice. 
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Figure  1.  Clinical course of EAMG in CD4+8 +, CD8 -/-, CD4 -/  , and CD4  8- C57BL/rJ  mice (n =  15 in each group). Mice were immunized 
with AChR plus CFA and boosted twice monthly. (*) Died; (+) humanely killed. 
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Figure 2.  Serum anti-M-AChR antibody levels in the different groups. 
The  antibody concentrations were  measured weekly  by  RIA  and ex- 
pressed as moles of {x-BGT-binding sites bound per liter of serum.  Sym- 
bols  refer  to  mean  values,  and  bars  to  SD.  The  differences  between 
CD4-8- and CD4+8 § mice were significant from week 2 p.i. up to end 
(significant  P values were omitted).  (*) P  <0.05 between CD4+8 + and 
CD8 -/  mice; (#) P <0.05 between CD4+8 + and CD4 -/- mice. 
Anti-AChR  Antibodies in  Serum and  AChR-specific  IgG 
Antibody-secreting Cells.  Serum  anti-M-AChR  antibodies 
were detected in the CD4+8 + wild-type mice from week 2 
p.i. The  levels increased gradually over the observation pe- 
riod  (Fig.  2).  In  contrast,  the  levels  of antibodies  in  the 
CD4-8-  mice  were  significantly lower  from  week  2  p.i. 
up to the end. The levels in the CD4 -/-  and CD8 -/-  mice 
were  also  significantly  lower  than  in  the  CD4+8 +  wild- 
type mice from week  5  p.i.  onwards,  except at a  few time 
points.  There  were  no  differences  in  antibody  levels  be- 
tween  CD4 -/-,  CD8 -/-,  and  CD4-8-  mice.  No  anti- 
AChR  antibodies were found in sera from the CFA-immu- 
nized control mice. 
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Figure 4.  Numbers ofAChR-reactive IFN-"/~secretmg T cells per l0  s 
MNC  isolated  from PILN,  spleen,  and thymus of the different groups. 
Symbols refer to mean values, and bars to SD. P values refer to compari- 
sons between the CD4+8 + mice and the other three groups.  (*) P <{).05; 
(**) P <{}.01, 
The highest numbers ofanti-AChR  IgG antibody-secret- 
ing cells were found in lymph nodes and the lowest in thy- 
mus (Fig. 3). Lymph nodes as well as spleens from CD4+8 + 
mice contained higher numbers of these cells than the other 
groups.  In  thymus,  numbers  of anti-AChR  IgG-secreting 
cells were  low throughout,  but a  significant difference  was 
noticed between  CD4+8 +  and CD4-8-  mice. 
AChR-reactive IFN-y-secreting  Cells.  As  shown  in  Fig. 
4,  the lymph nodes from CD4+8 +  EAMG  mice contained 
higher numbers ofAChR-reactive  IFN-'v-secreting T  cells 
compared  with  CD4-8-,  CD4 -/-,  or  CD8 -/-  mice.  In 
spleen,  CD4+8 +  mice  also  had  higher  numbers  of these 
cells than CD4-8-  and CD4 -/-  mice.  There  were  no dif- 
ferences  between  the  four  groups  in  thymus.  No  differ- 
ences  were  found  when  cells  from  lymphoid  organs were 
evaluated  in  control  experiments  after  culture  with  MBP 
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Figure  3.  Numbers ofanti-AChR IgG antibody-secreting cells per 105 
MNC  isolated  from PILN,  spleen,  and thymus of the different groups. 
Symbols refer to mean values, and bars to SD. P values refer to compari- 
sons between the CD4+8 + mice and the other three groups.  (*) P <0.05; 
(**) P <0.01; and (***) P <0.001. 
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Figure  5.  Proliferative  responses  to  AChR  by  MNC  from  PILN, 
spleen, and thynms of the different  groups.  Symbols refer to mean values, 
and bars to SD. Pvalues refer to comparisons between the CD4+8 + mice 
and the other groups.  (*) P <0.05; (**) P <0.01. 
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2.1/105 MNC), respectively. After culture with Con A  for 
MNC  from lymph nodes,  the  lowest numbers  of IFN-~/- 
secreting cells were found in CD4-8-  mice (6.5  +  2.4/10 s 
MNC)  and the highest in CD4+8 + mice  (13.6  +-  6.1/105 
MNC)  (P  <0.05).  No  differences  were  found  between 
other groups. 
AChR-induced Lymphocyte Proliferation.  Proliferative  re- 
sponses  to  AChR  were  higher  in  lymph  node  cells  of 
CD4+8 + mice compared with the other groups. Significant 
differences  were  also  found  in  spleens  between  CD4+8 + 
and CD4-8-  or CD8 -/- mice (Fig. 5). All groups showed 
similar high SI levels after stimulation by Con A  (5.4-9.0), 
and similar low SI levels after culture with the control anti- 
gen MBP (0.7-1.3). 
AChR-reactive  IFN-%  IL-4,  and  TGF-[3 mRNA-express- 
ing Cells.  Lymph  nodes  from  CD4+8 +  mice  contained 
higher numbers ofAChlk-reactive IFN-'y and IL-4 mRNA- 
expressing  cells  when  compared  with  CD4 -/-,  CD8 -/-, 
and  CD4-8-  mice.  The  numbers  of  IFN-~/-mRNA- 
expressing cells in CD4 -/-  mice were also higher than in 
CD4-8-  mice. There were no differences among the three 
groups  of mutant  mice  for IL-4 mRNA-expressing  cells. 
Numbers  of AChR-reactive  TGF-[3  mRNA-expressing 
cells were lower in CD4-8-  mice compared with CD4+8 + 
wild-type mice,  but not among the  other groups  (Fig.  6). 
No differences were detected between the four groups for 
MBP-induced  cytokine mRNA-expressing cells  (2.0-3.5/ 
105  MNC  for  IFN-%  1.3-2.5  for  IL-4,  and  2.6-3.3  for 
TGF-[3) or after culture of MNC  without antigen or mito- 
gen  (2.2-3.8  for  IFN-%  1.3-2.5  for  IL-4,  and  2.2-3  for 
TGF-[3).  After being stimulated  by Con A,  the numbers  of 
mRNA-expressiNg  cells  for  IFN-3'  were  43.6  --  9.7  in 
CD4-8-  mice arid 62.3  +  10.2 in CD4+8 + mice; for IL-4 
they were  5.3  -+  1.9 in CD4-8-  mice and  10.2  -+  4.0 in 
CD4+8 + mice (P <0.05,  respectively).  There were no dif- 
ferences between the other groups for IFN-y and IL-4, or 
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Figure  6.  Numbers of AChK-reactive  IFN-%  IL-4,  and  TGF-[3 
mRNA-expressing cells per 105 MNC isolated from PILN of the differ- 
ent groups. Symbols refer to mean values, and bars to SD. (*) P <0.05; 
(**) P <0.01 between the CD4+8 + mice and the other three groups; and 
(#) P <0.05 between CD4 -/- and CD4-8- mice. 
between  all  four groups  for TGF-13  (20.6  -+  4.7-35.3  + 
13.2/105 MNC). 
Discussion 
This study provides evidence that both CD4 and CD8 T 
cells are involved in the  induction  of EAMG as helper or 
effector  cells.  The  importance  of CD4 +  T  cells  in  the 
pathogenesis  of EAMG  is  in  line  with  previous  data  on 
EAMG and human MG  (6,  7,  10, 20).  However, the role 
ofCD8 + T  cells in EAMG is unclear. Shenoy et al.  (12) re- 
ported that [32  m-/-  mice with deficient MHC  class  I  ex- 
pression  and  low  CD8  cell  counts  showed  more  severe 
EAMG compared with controls, and postulated that the in- 
creased disease  severity was a result of a lack of regulator/ 
suppressor  CD8 +  T  cells  (12).  By  using  CD8 -/-  and 
CD4-8-  mice,  we  now  present  evidence  that  CD8 +  T 
cells also function as effector/helper cells in EAMG. There 
are  several  reasons  why  results  between  CD8 -/-  and 
[32  m-/-  mice differ.  (a)  132  m-/-  mice indeed process func- 
tional CD8 + T  cells (21, 22). After in vivo priming and in 
vitro  restimulation  with H-2  d spleen  cells,  132  m-/-  (H-2  b) 
responder  mice  developed  the  same  strong  cytotoxic  re- 
sponses  against  the  allospecific  H-2a-expressing  targets  as 
[32  m+/-  control mice (21).  The specific ability of residual 
CD8 +  T  cells  in  [32m-deficient mice to react with  class  I 
H-2  b molecules  on normal H-2b-expressing cells indicates 
that  these  T  cells  have  not  undergone  negative  selection 
(23),  and  CD8 +  T  cells  specific  for  self-peptides  conse- 
quently may escape elimination.  (b) Besides their restriction 
by MHC  class I, CD8 + T  cells are also restricted by MHC 
class  II (24).  These class  II-restricted CD8 + T  cell subsets, 
which can secrete  IFN-%  IL-4, and  IL-10  (23),  wilt  sur- 
vive in [32m-deficient mice. (c) Rats depleted ofCD8 + cells 
with  mAb  had  less  severe  EAMG  accompanied  by  de- 
creased B and T  cell responses to AChlL (11). (d) An unex- 
pected  function  of MHC  class  I  was  observed  in  experi- 
mental SLE, an autoantibody-mediated disease,  since SLE- 
susceptible  mice lacking MHC  class  I did not develop any 
clinical  SLE  manifestations,  whereas  mice  depleted  of 
CD8 +  T  cells  remained  susceptible  (25).  These  data  indi- 
cate that  experimental  manipulation  of CD8 +  T  cells  will 
not parallel manipulation of MHC  class I. 
T  cells  have for a long time been functionally classified 
according to their  CD  phenotype,  i.e.,  CD4 +  T  cells  are 
helper/inducer  and CD8 + T  cells are suppressor/cytotoxic 
cells.  Recent studies suggest that the functions oft  cells are 
more complicated (26). There are suppressor CD4 + T  cells 
that  can  produce  TGF-[3  and  are  important  in  inducing 
tolerance  (27).  CD8 +  T  helper  cells  can  also be  classified 
into  Thl  and  Th2  subsets  according to  their  phenotypes 
and production of cytokines (28, 29). Based on the produc- 
tion oflL-4 and IFN-y, the CDw60+CD8 + cells are simi- 
lar to the  CD4 +  Th2 subset,  whereas  the  CDw60-CD8 + 
cells  resemble  the  Thl  subset  (28).  CD8 +  cells  were  also 
found to help  B  cells  in antibody production through the 
expression ofCD40 ligand (30).  Elimination of either CD4 + 
353  Zhang et al. or CD8 + T  cells suppresses some T  cell- or antibody-medi- 
ated experimental autoimmune diseases (31-34). The present 
study suggests that both CD4 + and CD8 + cells are essential 
for  the  development  of EAMG.  Interestingly,  in  human 
MG, there is a striking association with the MHC  class I al- 
lele HLA B8,  which is stronger (higher relative risk), than 
with the MHC  class II allele D1K3  (35).  In view of the fact 
that MHC  class I is the main restriction element for CD8 + 
T  cells,  the  present  observation  is  in  agreement  with  a 
MHC  class I association in MG. 
Mice  lacking CD4 +  T  cells have  normal  development 
and function ofCD8 + T  cells and some TC1K-c~/]3+CD4-8 - 
cells (36).  Mice lacking CD8 +  T  cells have normal devel- 
opment and function of CD4 + cells (37).  In CD4-8-  mu- 
tant  mice,  B  cells  and  TCR--ot/]3+CD4-8 -  cells  have 
expanded  to  occupy  the  compartment  that  would  other- 
wise  have  been  occupied by  CD4+8 -  and  CD4-8 +  cells 
(38). These results indicate that a reduced communication/ 
adhesion  between  antigen-specific T  cells and  APC,  as  a 
consequence  of  the  absence  of  marker  molecules  (i.e., 
CD4/CD8  surface  antigens)  in  remaining  T  cells,  might 
also play a role in the amelioration of EAMG in our animal 
model.  On  the  other hand,  CD4  or  CD8  cells separately 
are not sufficient to  induce EAMG,  suggesting that a  col- 
laboration between  CD4  and  CD8  T  cells may be  neces- 
sary. In EAE, it was speculated that CD4 + effector cells ini- 
tially home  to  the  central  nervous  system,  and  CD8 +  T 
cells are subsequently recruited and may subserve an effec- 
tor function  that augments  the  damage  of myelin  (31).  In 
nonobese diabetic mice, CD4 +  cells home to the pancreas 
and promote the influx of CD8 +  cells, which finally leads 
to  the  full  development of insulitis  (39).  Whether  or  not 
this  is  the  case  in  antibody-mediated EAMG  is  currently 
under investigation. 
The  Thl-associated proinflammatory IFN-y may play a 
role in both  human  MG  and EAMG  (5,  8).  In transgenic 
mice  expressing  IFN-y  in  neuromuscular junctions,  au- 
toantibody deposits at motor end plates imply that  IFN-y 
in  the  milieu of the  muscle  tissue  induces  humoral  auto- 
immunity (40). After tolerance induction by oral or nasal ad- 
ministration ofAChlZ, numbm~ ofAChlK-reactive IFN-y- 
secreting  cells  are  reduced  in  association  with  decreased 
muscular weakness (8,  41).  The present study suggests that 
both  CD4 +  and  CD8 +  antigen-specific  T  cells  produce 
IFN-y  and,  thereby,  provide  help  to  induce  EAMG.  In 
EAE, both CD4 + and CD8 + MBP-specific T  cells can se- 
crete large amounts of IFN-'y. Furthermore, oral tolerance 
to EAE could be established after depletion of either CD4 + 
or CD8 + T  cells (42).  Taken together,  IFN-y seems to be 
an  important  promotor  in  both  B-  and  T  cell-mediated 
autoimmune diseases. 
The decrease ofanti-AChlK antibodies in CD4 and CD8 
nmtant  mice  might  be  a  result  of reduced  levels of IL-4 
mRNA-expressing cells. IL-4 is involved in the differentia- 
tion  of resting B  cells to  lg-secreting cells (43)  and  is the 
major  anti-AChR  antibody-promoting  factor  (3).  It  has 
been  observed that human  MG  and EAMG are associated 
with elevated numbers  of IL-4 mRNA-expressing cells (16, 
44).  Besides CD4 +  T  cells, type 2  CD8 +  T  cells can pro- 
duce similar amounts or even two or three times more IL-4 
mRNA  (24).  Our  results  are  in  line  with  these  observa- 
tions. In the present study, lack of either CD4 + or CD8 + T 
cells does not substantially decrease the amounts of TGF-]3, 
whereas lack of both subsets does, indicating that both CD4 + 
and  CD8 +  T  cells are to  some  extent  sources  of TGF-]3. 
Though  TGF-]3 functions as an  immunosuppressive cyto- 
kine, the increased TGF-]3 anmunts  in wild-type CD4+8 + 
mice  are not  high  enough  to  counteract  disease develop- 
ment.  It can be concluded that the suppression of EAMG 
in CD4- and/or CD8-knockout mice is mainly caused by a 
decrease  in  the  production  of effectors  like  IFN-'y  and 
IL-4, but not mediated by TGF-~. 
Notably,  CD4-8-  mice  developed  some  amounts  of 
anti-AChR  antibodies in  serum  after  inmmnization  with 
AChR  plus CFA.  This  would suggest  that B  cells can  be 
activated to produce anti-AChlK antibodies to some degree 
without  the help of costimulatory cell surface antigens  on 
CD4 +  and  CD8 +  cells. Another possibility is that,  besides 
T  cells, additional types of cells such  as macrophages  (45) 
can provide B  cell help.  Further studies defining the  roles 
of immune  cells beyond T  cells are thus  crucial to  under- 
stand the development of MG and EAMG. 
We thank professor  Tak W. Mak for providing the CD4  /-,  C1)8-  , and CD4-8-  mutant C57BL/6J 
mice, and Dr. Hans-GustafLjunggren for helpful discussion of the manuscript. 
This study was supported by grants from the Swedish  Medical Research Council, the Swedish MS Society 
(NHR), Karolinska Institute, and the AFA Foundation. 
Address correspondence to Dr. Guang-Xian Zhang, Division of Neurology, Huddinge Hospital, S-14l 86 
Huddinge, Stockholm, Sweden. 
Received for publication  19 Februa~  T  1996 and in revised  form 23 April  I996. 
References 
1.  Berman,  P.W., and J.  Patrick.  1980.  Experimental myasthe- 
nia gravis--a murine system.J. Exp. Med. 15l:204-223. 
2.  Drachman, D. 1994. Myasthenia gravis. N. Etl,  gl.l. e~h'd. 330: 
1797-1810. 
3.  Asthana,  D.,  Y.  Fujii, G.  Huston,  and J.  Lindstrom.  1993. 
Regulation of antibody production by helper T  cell clones in 
354  CD4 + and CD8 + T Cells in Experimental Autoimmune Myasthenia Gravis experimental autoimmune myasthenia gravis is mediated by 
IL-4 and antigen-specific T cell factors. Clin.  Immunol.  lmmu- 
nopathol. 67:240-248. 
4.  Hohlfeld,  R.,  K.V.  Toyka,  S.J. Tzartos,  W.  Carson,  and 
B.M.  Conti-Tronconi. 1987. Human T  helper lymphocytes 
in myasthenia gravis recognize the nicotinic receptor subunit. 
Proc. Natl. Acad. Sci. USA.  84:5379-5383. 
5.  Link, H.,  O.  Olsson, J.B.  Sun, W.Z. Wang, G. Andersson, 
H.P. Ekre,  T. Brenner, O. Abramsky,  and T. Olsson.  1991. 
Acetylcholine receptor reactive  T  and B cells in myasthenia 
gravis and controls.J. Clin.  Invest. 87:2191-2196. 
6.  Fujii, Y., andJ. Lindstrom. 1988. Specificity of the T cell im- 
mune response to acetylcholine receptor in experimental au- 
toimmune myasthenia gravis. Response to subunits and syn- 
thetic peptides.J. Immunol.  140:1830-1837. 
7.  Lennon, V.A.,  D.J. McCormick, E.H. Lambert, G.E. Gries- 
mann, and M.Z. Atassi. 1985. Region ofpeptide 125-147  of 
acetylcholine receptor alpha subunit is exposed at neuromusclar 
junction and  induces  experimental  autoimnmne myasthenia 
g-cavis. T cell immunity, and modulating autoantibodies. Proc. 
Natl. Acad. Sci. USA.  82:8805-8809. 
8. Wang, Z.Y., J.  Qiao, A. Melms, and H.  Link. 1993. T  cell 
reactivity to acetylcholine receptor in rats orally tolerized against 
experimental autoimmune myasthenia gravis. Cell.  Immunol. 
152:394-404. 
9.  Christadoss,  P.,  and M.  Dauphinee.  1986.  Immunotherapy 
for  myasthenia  gravis:  a  murine  model. J.  Immunol.  136: 
2437-2440. 
10. Kaul, R., M. Shenoy, E. Goluszko, and P. Christadoss.  1994. 
Major histocompatibility class II gene disruption prevents ex- 
perinaental  autoimmune myasthenia gravis. J.  Immunol.  152: 
3152-3157. 
11. Zhang, G.X., C.G. Ma, B.G. Xiao, M. Bakheit,  H. Link, and 
T. Olsson.  1995. Depletion of CD8 + T  cells suppresses ex- 
perimental autoimmune myasthenia gravis in Lewis rats. Eur. 
J. Immunol.  25:1191-1198. 
12. Shenoy, M., R. Kaul, E. Goluszko,  C. David, and P. Christa- 
doss. 1994. Effect of MHC class I and CD8 cell deficiency on 
experimental autoimmune myasthenia gravis pathogenesis. J. 
lmmunol.  152:5330-5335. 
13. Lindstrom, J., B. Einarson, and S. Tzartos.  1981. Production 
and assay of antibodies to  acetylcholine receptors.  Methods 
Enzymol. 74:432-460. 
14. Deibler, G.E., R.E. Martenson, and M.V. Kies.  1972. Large 
scale preparation of myelin basic protein from central nervous 
tissue  of several  mammalian species. Prep. Biochem.  2:139- 
165. 
15. Van der Meide, P.H., M.  Dubbeld, K. Vijverberg,  T.  Kos, 
and H. Schellekens.  1986. The purification and characteriza- 
tion of rat gamma interferon by use of two monoclonal anti- 
bodies.J. Gen.  Virol. 67:1059-1071. 
16. Wang, Z.Y., H. Link, .~.. Ljungdahl, B. H6jeberg, J. Link, J. 
Qiao, A. Melms, and T. Olsson. 1994. Induction of IFN-% 
IL-4 and TGF-[3 in rats orally tolerized against experimental 
autoimmune myasthenia gravis. Ceil. Immunol.  157:353-368. 
17. Dijkema, R., P.H. van der Meide, M. Dubbeld, J.  Wubben, 
and H. Schellekens.  1986. Cloning, expression  and purifica- 
tion of rat IFN-% Methods Enzymol.  119:453-463. 
18. McKnight, A.J., A.N. Barclay, and D.W. Mason. 1991. Mo- 
lecular cloning of rat interleukin 4 cDNA and analysis of the 
cytokine repertoire of subsets of CD4 + T cells. Eur. J. lmmu- 
nol. 21:1187-1194. 
19. Derynck, R., J.A. Jarrett,  E.Y.  Chen, D.H. Eaton, J.R. Bell, 
R.K. Assoian, A.B. Roberts, M.B. Sporn, and D.V. Goeddel. 
1985. Human transforming growth factor-J3 complementary 
DNA  sequence and expression  in normal and transformed 
cells. Nature (Lond.). 316:701-705. 
20. Waldor, M., S. Sriram, H. McDevitt, and L. Steinman. 1983. 
In  vivo  therapy  with  monoclonal anti-I-A antibody sup- 
presses immune responses to acetylcholine receptor.  Immunol- 
ogy. 80:2713-2717. 
21. Glas, R.,  C.  Ohlen, P.  H6glund, and K. K~irre. 1994. The 
CD8 + T  cell repertoire in [32-microglobulin-deficient  mice 
is biased towards reactivity against self-major histocompatibil- 
ity class I.J. Exp. Med.  179:661-672. 
22. Bix,  M., and D.  Raulet.  1992. Functionally conformed free 
class I heavy chains exist on the surface of [32 microglobulin 
negative cells.J.  Exp. Med.  176:829-834. 
23. Ljunggren,  H.-G.,  L.V.  Kaer,  P.G.  Ashton-Rickardt,  S. 
Tonegawa, and H.L.  Ploegh.  1995. Differential  reactivity  of 
residual CD8 + T lymphocytes in TAP1 and [32-microglobu- 
lin mutant mice. Eur.J. Immunol. 25:174-178. 
24. Kemeny, D.,  A.  Noble, B.  Holmes, and D.  Diaz-Sanchez. 
1994. Immune regulation: a new role for the CD8 + T  cells. 
Immunol.  Today. 15:107-110. 
25. Mozes,  E.,  L.D.  Kohn,  F.  Hakim,  and D.S.  Singer.  1993. 
Resistance of MHC class I-deficient mice to experimental sys- 
temic lupus erythematosus.  Science (Wash.  DC). 261:91-92. 
26. Kelso, A. 1995. Thl and Th2 subsets: paradigms lost? Immu- 
nol. Today. 16:374-379. 
27. Karpus,  W.J.,  and R.H.  Swanborg. 1991.  CD4 + suppressor 
cells inhibit the function of effector cells of experimental au- 
toimmune encephalomyelitis though a mechanism involving 
transforming growth factor-]3. J. Immunol.  146:1163-1168. 
28. Rieber, E.P.,  and G. Rank. 1994. CDw60: a marker for hu- 
man CD8 + T helper cells.J.  Exp. Med.  179:1385-1390. 
29. Salgame, P., J.S. Abrams, C. Clayberger, H. Goldstein, J. Con- 
vit, R.L. Modlin, and B.R. Bloom. 1991. Differing lympho- 
kine profiles of functional subsets of human CD4 and CD8 T 
cell clones. Science (Wash.  DC). 254:279-282. 
30. Seder,  R.A.,  and G.L.  Gros.  1995. The functional role  of 
CD8 + T helper type 2 cells.J.  Exp. Med.  181:5-7. 
31. Koh, D.R., W.P.  Fung-Leung, A.  Ho,  D.  Gray,  H. Acha- 
Orbea,  and T.W.  Mak.  1992.  Less mortality but more re- 
lapses in experimental allergic encephalomyelitis in CD8 -/- 
mice. Science (Wash.  DC). 256:1210-1213. 
32. Fowell, D.,  and D.  Mason.  1993. Evidence that the T  cell 
repertoire of normal rats contains cells with the potential to 
cause  diabetes.  Characterization of the  CD4  + T  cell subset 
that  inhibits this  autoimmune potential. J.  Exp.  Med.  177: 
627-636. 
33. Kong, Y., H. Waldmann, S. Cobbold, A. Giraldo,  B. Fuller, 
and L. Simon. 1989.  Pathogenic mechanisms in murine au- 
toimmune thyroiditis:  short- and long-term effects of in vivo 
depletion ofCD4 + and CD8 + cells. Clin.  Exp.  Immunol.  77: 
428-433. 
34. Pummerer, C., P. Berger,  M.  Fruhwirth, C.  C)fner, and N. 
Neu.  1991. Cellular infiltrate,  major histocompatibility anti- 
gen expression  and immunopathogenic mechanisms in car- 
diac myosin-induced  myocarditis. Lab. Invest. 65:538-547. 
35. Dawkins, R.L., F.T. Christiansen, P.H. Kay, M. Garlepp, J. 
McCluskey, P.N. Hollingsworth, and p.J.  Zilko. 1983. Dis- 
ease associations with complotypes,  subtypes and haplotypes. 
Immunol. Rev. 70:5-22. 
36. Rahemtulla, A.,  W.P.  Fung-Leung, M.W.  Schilham,  T.M. 
Kundig,  S.R.  Sambhara,  A.  Narendran,  A.  Arabian,  A. 
355  Zhang et al. Wakeham, C.J. Paige, P,.M.  Zinkernagel, et al.  1991.  Nor- 
mal development and function of CD8 + cells but markedly 
decreased helper cell activity in  mice lacking CD4.  Nature 
(Loud.).  353:180-184. 
37.  Fung-Leung, W.P.,  M.W.  Schilham, A.  Rahemtulla,  T.M. 
Kundig,  M.  Vollenweider, J.  Potter,  W.  van  Ewijk,  and 
T.W. Mak.  1991.  CD8 is needed for development of cyto- 
toxic T cells but not helper T cells. Cell.  65:443-449. 
38. Schilham,  M.W.,  W,P.  Fung-Leung,  A.  Rahemtulla,  T. 
Kundig,  L.  Zhang, J.  Potter,  P,.G.  Miller,  H.  Hengartner, 
and T.W. Mak. 1993.  Alloreactive cytotoxic T  cells can de- 
velop and function in mice lacking both CD4 and CD8. Eur. 
J. Immunol.  23:1299-1304. 
39.  Thivolet, C.A., A. Bendelac, P. Bedossa, J-F. Bach,  and C. 
Carnaud.  1991.  CD8 + T  cell homing to the pancreas in the 
nonobese diabetic mouse is CD4 + T  cell-dependent. J.  Irn- 
munot.  145:85-93. 
40. Gu,  D.,  L.  Wogensen,  N.A.  Calcutt,  C.  Xia,  S.  Zhu, J.P. 
Merlie, H.S. Fox, J. Lindatrom, H.C. Powell, and N. Sarvet- 
nick. 1995. Myasthenia gravis-like syndrome induced by ex- 
pression  of interferon-"/ in  the  neuromuscular junction. J. 
Exp. Med.  181:547-557. 
41. Ma, C.G., G.X. Zhang, B.G. Xiao, J.  Link, T.  Olsson, and 
H.  Link.  1995.  Suppression  of experimental  autoimmune 
myasthenia gravis with nasal  administration of acetylcholine 
receptor.J. Neuroimmunol.  58:51-60. 
42.  Chen, Y.,J. Inobe, and H.L. Weiner. 1995.  Induction of oral 
tolerance  to  myelin  basic  protein  in  CD8-depleted  mice: 
both CD4 + and CD8 + cells mediate active suppression.J. Im- 
munol.  155:910-916. 
43. Lanzavecchia, A. 1985.  Antigen-specific interaction between 
T and B cells. Nature (Lond.).  314:537-539. 
44.  Link, J., M. SSderstr6m, A. Ljungdahl, B. HSjeberg, T. Ols- 
son, Z. Xu,  S. Fredrikson, Z.Y. Wang, and H. Link.  1994. 
Organ-specific autoantigens induce IFN-y and IL-4 mRNA 
expression in mononuclear cells in multiple sclerosis and my- 
asthenia gravis. Neurology.  44:728-734. 
45. Kinoshita, I., T. Nakamura, A. Satoh, H. Matsuo, M. Seto, I. 
Tomita, M. Tsujihata, and S. Nagataki. 1988.  Role of mac- 
rophage in the pathogenesis of experimental autoimmune my- 
asthenia gravis.J. Neurol.  Sci. 87:49-59. 
356  CD4 + and CD8 + T Cells in Experimental Autoimmune Myasthenia Gravis 